Conversion from cyclosporin to tacrolimus in paediatric liver transplant recipients

Paediatric Drugs

Volumn 3, Issue 9, 2001, Pages 661-672

  Mazariegos, G V ^a   Salzedas, A A ^b   Jain, A ^a   Reyes, J ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS;

CHILD; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; DRUG MECHANISM; EPSTEIN BARR VIRUS; GINGIVA HYPERPLASIA; GRAFT REJECTION; GROWTH RETARDATION; GYNECOMASTIA; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NEUROTOXICITY; PATIENT COMPLIANCE; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0034771807     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103090-00004     Document Type: Review

References (48)

1. Evolution of liver transplantation
2. Comparative evaluation of tacrolimus (FK506) and cyclosporin A as immunosuppressive agents
3. A comparison of tacrolimus FK506 and cyclosporin for immunosuppression in liver transplantation
4. Long-term outcomes in pediatric liver recipients: Comparison between cyclosporin A and tacrolimus
5. Conversion from cyclosporin to FK 506 in liver allograft recipient with cyclosporin-related complications
6. Use of FK 506 for treatment of chronic rejection after liver transplantation
7. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients
8. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection
9. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients
10. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
11. The Pittsburgh randomized trial of tacrolimus compared to cyclosporin for hepatic transplantation
12. Two-year experience with FK506 in pediatric patients
13. Conversion of liver allograft recipients from cyclosporin to FK506 immunosuppressive therapy: A clinicopathologic study of 96 patients
14. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation
15. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection
16. Conversion from cyclosporin to FK506 for salvage of immunocompromised pediatric liver allografts
17. FK506 conversion therapy in pediatric liver transplantation
18. The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients
19. Tacrolimus for steroid-resistant liver rejection in children
20. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporin
21. Long-term results after conversion from cyclosporin to tacrolimus in pediatric liver transplantation for acute and chronic rejection
22. Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation
23. Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: Experience in 20 children
24. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation
25. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients
26. Mycophenolate mofetil in liver transplantation
27. The effect of conversion from cyclosporin to tacrolimus on gingival hyperplasia, hirsutism and cholesterol
28. Treatment of cyclosporin-related adverse effects by conversion to tacrolimus after liver transplantation
29. Early complications after orthotopic liver transplantation
30. Noncompliance after pediatric liver transplantation
31. Causes of late mortality in pediatric liver transplant recipients
32. Weaning of immunosuppression in liver transplant recipients
33. Management of acute steroid-resistant rejection after liver transplantation
34. The use of tacrolimus in pediatric liver transplantation
35. Early use of tacrolimus as rescue therapy for refractory liver allograft rejection
36. Conversion from cyclosporin to FK506 after liver transplantation
37. Long term management of liver transplant rejection in children
38. What have we learned about primary liver transplantation under tacrolimus immunosuppression: Long-term follow-up of the first 1000 patients
39. Tacrolimus and myocardial hypertrophy
40. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients
41. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation
42. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation
43. Comparative long term evaluation of tacrolimus and cyclosporin in pediatric liver transplantation
44. A long term comparison of tacrolimus (FK506) versus cyclosporin in liver transplantation: A report of the United States FK506 study group
45. Management of posttransplantation lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy
46. Posttransplantation lymphoproliferative disease in pediatric liver transplantation
47. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients
48. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients